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Abstract
Background: Norcantharidin (NCTD) is a Chinese FDA approved, chemically synthesized drug for cancer treatment.
The effect of NCTD on signaling proteins of EGFR and c-Met was systematically elucidated in current study.
Methods: Two human colon cancer cell lines, HCT116 and HT29, were used as model systems to investigate the
anti-cancer molecular mechanism of NCTD. Cell cycle arrest and early/late apoptosis were analyzed by flow
cytometry. The levels of EGFR, phospho-EGFR, c-Met, phospho-c-Met and other related proteins were quantified by
western blot analysis.
Results: NCTD induced cell cycle arrest at G2/M phase in both cell lines. The early and late apoptosis was also
observed. Further investigation indicated that NCTD suppressed not only the expression of the total EGFR and the
phosphorylated EGFR but also the expression of the total c-Met and the phosphorylated c-Met in colon cancer
cells. Moreover, EGFR expression could be mostly restored by co-treatment with MG132, a proteasome inhibitor. In
addition, NCTD-induced cell death was comparable to that of the anti-cancer drug gefitinib, a tyrosine kinase
inhibitor for EGFR, based on the immunoblot analysis of the expressed proteins after the drug treatment.
Conclusions: NCTD might be a useful and inexpensive drug candidate to substitute for gefitinib to serve the
treatment needs of cancer patients.
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Background
Cantharidin (CTD) is isolated from Mylabris phalerata
Pall, a valued traditional Chinese medicine in treating
skin problems, such as furuncles and piles, for more
than 2000 years in China. In recent years, CTD has been
identified as the active compound in Mylabris phalerata
Pall with anti-tumor activity [1–4]. However, it causes
severe side effects in the urinary system both in animals
and in human [5]. Norcantharidin (NCTD), which is
chemically demethylated from CTD (Fig. 1), overcomes
the urological toxicity while enhancing its anti-tumor ac-
tivity [6]. Based on the cinical studies, NCTD has been
approved by Chinese FDA for liver, esophageal, and gas-
tric cancer treatment in China since 1996.
Numerous studies have indicated that NCTD possessed
the abilities to induce cell death for multiple types of can-
cer cells, for example, colorectal and lung cancer cells.
The anti-cancer activity of NCTD relies on its ability in
activation of the caspase signaling pathway that leads to
apoptosis [7] accompanied with a decreased ratio of Bcl-
2/Bax [8, 9], the changes in the expression of cell cycle-
related proteins are co-related with cell cycle arrest [10],
the interruption of DNA synthesis [11], inhibition of
tumor invasion and metastasis [12, 13], MAPK activation,
and protein kinase C pathway activation [14].
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Colon cancer is the fourth most common cancer in
the world found in both men and women. It is well
known that two cell surface receptor tyrosine kinases, c-
Met and EGFR, are co-present in 78% [15] to 80% [16,
17] in colon cancer cells. EGFR and c-Met corroborate
the downstream signaling pathways in cancer cells in
that c-Met and EGFR activate many of the same down-
stream signaling molecules. c-Met signaling is mainly re-
sponsible for cancer cell survival when EGFR inhibitors,
such as gefitinib, are used during cancer treatment [18].
So far, few c-Met inhibitors or c-Met pathway antago-
nists have been developed into drugs. Even though sev-
eral novel compounds are in clinical trials, their
potential use might be limited by their potency, pharma-
cokinetic defect, and safety profile [19]. Therefore, it is
highly desirable to find dual inhibitor for both EGFR
and c-Met, especially from the existing drugs, to facili-
tate colon cancer treatment.
In current study, we demonstrated that NCTD sup-
pressed the expressing level and phosphorylation of both
c-Met and EGFR. Moreover, NCTD-induced cell death
was comparable to that of the anti-cancer drug gefitinib,
a tyrosine kinase inhibitor for EGFR, based on the im-
munoblot analysis of the expressed proteins after the
treatment of NCTD.
Methods
Cell-related experiment and NCTD treatment
HT29 and HCT116, two human colon cancer cell lines,
were obtained, maintained, and passaged using the iden-
tical protocol described in the published report [20].
NCTD was obtained from National Institutes for Food
and Drug Control (Shandong, China). NCTD was dis-
solved in dimethylsulfoxide (DMSO) and the final con-
centration of DMSO used was 0.1% in culture media for
all experiments.
Cell growth inhibition assay
HT29 and HCT116 cells suspended in complete media
were seeded in 96-well plates (2000 cells/well). After
growing for 24 h in incubator, media were aspirated and
0.2 mL complete media containing serial concentrations
of NCTD were added to each well. After incubating the
plate for 24, 48, or 72 h, 20 μL of resazurin (2 mg/mL
dissolved in water, Sigma) was added to each well. The
fluorescent signal was monitored using 544 nm excita-
tion and 595 nm emission wavelengths by Spectramax
M5 plate reader (Molecular Devices) after incubation at
37 °C for 16 h in the incubator. The number of living
cells in each well was proportional to the relative fluor-
escence unit (RFU) measured by the assay [20].
Cell cycle analyses
HCT116 and HT29 cells were added in 6-well plates
with 6 × 104 cells/well with 2 mL complte media per
well. After incubation for 24 h, different concentrations
of NCTD in 2 mL of complete media was added to treat
cells. After 24 h incubation, the cell pellets were col-
lected using the published protocol [20] and resus-
pended in 1 mL of 70% ethanol at 4 °C overnight. For
analysis, the supernatant was removed by centrifuging at
1600 g for 1 min. The cell pellets were incubated with
0.5 mL PI/RNase Staining Buffer (BD Biosciences) for
15 min at room temperature. Single-cell suspension was
generated by gentle pipetting. The cells was analyzed
using Beckman cell analyzer FC500-mpl. Beckman CXP
software and Multicycle software were used for data
analysis.
Apoptosis assay
Annexin V/propidium iodide (PI) double staining assay
(BD Biosciences, San Diego CA, USA) was used to
quantify the apoptotic cells by following the manufac-
turer’s instruction [21]. Briefly, HCT116 and HT29 cells
were treated with different concentration of NCTD in
complete cell culture media for 24 h. After removing
NCTD-containing media, cells were incubated in 100 μL
buffer containing Annexin V and PI at room
temperature for 15 min. Beckman cell analyzer FC500-
mpl was then used to analyze the apoptotic cells.
Western blot analysis
HCT116 and HT29 cells were cultured in 10-cm dishes
for 24 h before treated with different concentrations of
NCTD or NCTD plus MG132 (Beyotime biotechnology,
China). After being incubated with another 72 h, the
cells were collected with cell-scrapers into 1.5 mL tube
and put on ice for 30 min in whole cell lysis buffer (Cell
Signaling Technology, USA) containing protease inhibi-
tors. Proteins were quantified by BCA protein assay kit.
Equal amount of proteins from different sample (50 μg)
were resolved over 8 or 12% SDS-polyacrylamide gel by
electrophoresis and then transferred to nitrocellulose
membrane. The membranes were put in blocking buffer
at room temperature for 2 h before appropriate primary
Fig. 1 The structure of norcantharidin (NCTD) and cantharidin (CTD)
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antibody was added. The membrane was incubated in
the presence of primary antibody at 4 °C overnight be-
fore the corresponding secondary antibodies were added.
The membranes were then visualized by using Western
Lightning. Antibodies for EGFR, Phospho-EGFR
(Tyr1068), Her-2, Phospho-Her2/ErbB2 (Tyr1248), c-
Met, Phospho-c-Met (Tyr1003), Caspase-3, Rb, β-Actin,
PARP, CDK-2, CyclinD1, and Bax were purchased from
Cell Signaling Technology (USA).
Results
NCTD inhibited HCT116 and HT29 cell proliferation
The inhibitory effects of NCTD on cell proliferation of
HCT116 (Fig. 2a) and HT29 (Fig. 2b) were detected by
the resazurin assay. As shown in Fig. 2, NCTD induced
time- and concentration-dependent cell death in both
HCT116 and HT29 cells. Clinically, NCTD (Mw 168)
comes either as tablets to take by mouth (5-15 mg, 3
times a day) or to take by injections (10–20 mg/day). A
patient generally has 4 to 5 l of blood. Therefore, the
maximum concentrations of NCTD in patient’s blood
should be around 4–5 μg/mL (24–30 μM). The data in
Fig. 2 showed that 100 μM (16.8 μg/mL) NCTD induced
>50% cell death in both cancer cell lines at all the time
(24, 48, and 72 h) points tested. Based on the data,
NCTD were further studied from 6.25 to 100 μM in
both cancer cell lines for different types of tests.
NCTD suppressed the expression and activation of c-Met
and EGFR in HCT116 and HT29 cells
To understand the NCTD-induced cytotoxicity, we
tested the activation and expression of the EGFRs and c-
Met after NCTD treatment. As shown in Fig. 3a, NCTD
at 25 μM suppressed the phosphorylation of EGFR
(Tyr1068) by 50%, however, NCTD moderately de-
creased the level of EGFR even up to 100 μM. Her-2 is
another predominant member of EGFR family. Treat-
ment of NCTD also significantly decreased the level of
Her-2 and phosphor-Her-2 in dose-dependent manner.
Importantly, NCTD substantially decreased expression
of both phospho-c-Met and total c-Met. For example,
NCTD at 6.25, 25, 100 μM decreased the level of
phosphor-c-Met by 50, 60, 92% while inhibited the ex-
pression of total c-Met by 30, 50, 96%, respectively. Par-
allelly, HT29 responded to NCTD in the same trend, i.e.,
NCTD suppressed the activation of EGFR, Her-2 and c-
Met in dose-dependent manner (Fig. 3b).
To evaluate the potency of NCTD in killing colon can-
cer cells, we used gefinitib, the EGFR inhibitor, as the
positive control. We compared the effect of gefinitib on
attenuating the expression of the same group proteins,
i.e., EGFR, Her-2 and c-Met, at two concentrations of
25 μM and 50 μM, respectively. Based on the protein
band intensities, we found that NCTD exhibited stron-
ger inhibitory effect on phosphorylation of c-Met, EGFR,
and Her-2 at the concentration tested despite the ex-
pression of phosphor-Her-2 at 50 μM. Altogether, we
concluded that NCTD was comparable to gefinitib in at-
tenuating colon cancer cell growth (Fig. 3c).
In a time-dependent study, HCT116 cells were treated
by NCTD at 100 μM for a period up to 72 h. The same
group of proteins including c-Met, EGFR, Her-2, were
analyzed again by western blot analysis. Decrease of total
and phospho-c-Met, EGFR, Her-2 occurred in the 6 to
24 h and persisted for up to 72 h (Fig. 3d) by NCTD
treatment.
The mechanisim of the downregulation of EGFR in-
duced by NCTD in HCT116 cell was further invesiti-
gated by co-treatment in combination with MG132, a
proteasome inhibitor. As showed in Fig. 3e, NCTD in-
duced 50% decrease in EGFR expression while NCTD
plus MG132 induced 20% decrease in EGFR which indi-
cated NCTD inhibited EGFR expression mainly via
proteasome-mediated degradation.
G2/M cell cycle arrest induced by NCTD
To understand how NCTD induced cell death in both
cell lines, flow cytometry assay was used to study the
Fig. 2 Effect of NCTD on cell viability. HCT116 (a) and HT29 (b) human colon cancer cells were seeded in 96-well plates with 2000 cells/well, respectively.
After 24 h, cell culture media were replaced with 200 μL complete media containing serial concentrations of NCTD to treat the cells within the time of
period indicated. The viable cells were measured by the fluorescent signal as described in the Material and Methods Section. The experiments were
repeated for three times
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effect of NCTD on cell cycle after treating the cells with
varied concentrations of NCTD. NCTD caused G2/M
phase cell population accumulation in a dose-dependent
manner in HCT116 cells compared to that of control
(Fig. 4b), which was consistent with previous report [22].
For example, at the concentration of 12.5 and 50 μM,
NCTD induced an increase in G2/M phase cell popula-
tion by 2.2- to 4-fold, respectively. Similar results were
observed in HT29 cell line when the concentration of
NCTD was above 50 μM. Interestingly, the cell popula-
tion of G2/M phase had no change when the NCTD
concentrations were below 25 μM (Fig. 4c).
NCTD induced early/late apoptosis
We also measured the degree of apoptosis induced by
NCTD. As shown in Fig. 5a, compared to the control,
treating HCT116 cells with NCTD increased the
percentage of early and late apoptotic cells significantly
in a concentration-dependent manner (Fig. 5a). For ex-
ample, NCTD at 100 μM increased early apoptotic cell
population by 38.44-fold over the control cells, which
was similar for HT29 cells (Fig. 5b).
NCTD affected cell cycle- and apoptosis-related proteins
How NCTD affected cell cycle- and apoptosis-related sig-
naling proteins was tested over a range of concentrations
from 6.25 to 100 μM in both cell lines for 72 h. At 25 μM
concentration of NCTD, the level of cleaved PARP were
increased significantly and the cleaved caspase-3 was also
to show up (Fig. 6a). However, another apoptosis-related
protein, Bax, barely changed under this concentration.
Meanwhile, the decrease on several cell cycle-related pro-
teins including CyclinD1, Rb, CDK-4 was observed after
treatment with 12.5 to 100 μM of NCTD. In addition,
Fig. 3 Effects of NCTD on the expression and activation of EGFR and c-Met on HCT116 (a) and HT29 (b) human colon cancer cells. The cells were
seeded in 10-cm dishes for 24 h, and then cells were treated with NCTD or gefitinib (c) at 6.25, 12.5, 25, 50, and 100 μM, respectively. After 72 h of
incubation, cells were harvested for western blot analysis. Cells were treated with 100 μM of NCTD for the indicated periods after which the cells were
collected and prepared for western blot analysis (d). HCT116 cells were treated with 50 μM NCTD or 50 μM NCTD plus 0.2 μM MG132 for 48 h (e). The
expression of EGFR or β-Actin protein was detected by western blot analysis. The numbers underneath the blots represent band intensities (normalized
to the loading controls, means of three independent experiments) measured by the Image J software. The standard deviations were all within ±15%
of the means (data not shown). β-Actin was used as equal loading controls. The experiments were repeated for three times
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similar trends were detected when HT29 cell line was
used to perform the same test. In conclusion, NTCD af-
fected both cell cycle- and apoptosis-related signaling pro-
teins in a concentration-dependent manner (Fig. 6b).
Disscussion
Accumulating evidences indicated that both c-Met and
EGFR were overexpressed by 78 to 80% of colon can-
cers, which were associated with poor outcome. A cross-
talk of c-Met and EGFR could modulate reciprocally and
eventually determine the intensity of c-Met signaling
pathway [18]. One of the major findings of our study
was that the mechanism underlying the cell death in-
duced by NCTD involved in suppressing the expression
and phosphorylation of c-Met and EGFR. To our know-
ledge, this is the first demonstration that NCTD was a
dual inhibitor for c-Met and EGFR and in human colon
cancers.
Another interesting finding was that signaling network
might also exist between c-Met and Her-2 in colon can-
cer cells where the level of the two proteins decreased
with the increased concentration of NCTD. However,
we could not draw a conclusion how c-Met affected the
expression and activation of Her-2, such as by direct
suppression or indirect regulation. Additional studies
were necessary to reveal the potential mechanism how
Fig. 4 Cell cycle distribution of HCT116 (a) and HT29 (b) human colon cancer cells after treatment with NCTD. The cells were seeded in 6-well plates
for 24 h and then treated with NCTD in complete media. After 24 h treatment, cells were harvested and subjected to cell cycle analyses as described
in Materials and Methods. All data represent mean ± SD. Statistical analysis were conducted among control and treated groups in G0/G1, S and G2/M
phases separately. Statistical significance was determined by Student’s t test (p < 0.001). * represent significant difference in cell number in the control
that received PBS versus those treated with the indicated concentration of NCTD. Each bar represents the average value ± S.D; n = 3
Fig. 5 Effect of NCTD on apoptosis in HCT116 (a) and HT29 (b) cells.
The cells were seeded in 6-well plates for 24 h, and then the cells were
treated with serial concentrations of NCTD. After 48 h of treatment,
cells were harvested and subject to apoptosis analyses as described in
Materials and Methods. The experiments were repeated for three times.
Statistical significance was determined by Student’s t test (p < 0.001). *
represent significant difference in cell number in the control that
received PBS versus those treated with the indicated concentration of
NCTD. Each bar represents the average value ± S.D.; n = 3
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c-Met downregulated Her-2 expression in colon cancer
cells line.
With the dramatic effects against lung cancer, gefitinib
has been the most used small molecular EGFR inhibitor.
To evaluate the potency of NCTD in killing colon can-
cer cells, gefitinib was used as the positive control in our
study. Our data showed that NCTD was better at sup-
pressing the phosphorylation of EGFR tested at 25 μM
while gefinitib exhibited stronger inhibitory effect on the
phosphorylation of Her-2 at 50 μM. Collectively, the
data suggested that NCTD might have a different mech-
anism from gefitinib in killing colon cancer cells. Re-
markably, although the two drugs exhibited comparative
effect on attenuating the EGFR, Her-2, and c-Met,
NCTD seemed to possess certain advantages over gefi-
tinib including lower cost, better safety, and superior tol-
erance of NCTD [6] (Fig. 7).
Conclusions
In conclusion, NCTD suppressed the phosphorylation
and expression of both EGFR and c-Met in HCT116
and HT29 human colon cancer cells. Our data provided
novle molecular mechanism for further investigation if
NCTD could serve as a dual inhibitor for EGFR/c-Met
in terms of colon cancer treatment.
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